CAMP4 Therapeutics Corporation Unbilled Receivables, Current
CAMP4 Therapeutics Corporation (CAMP) had Unbilled Receivables, Current of $0 as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:UnbilledReceivablesCurrent · last filed 2026-08-13
- 2026-06-30: Unbilled Receivables, Current $0.00.
- 2025-12-31: Unbilled Receivables, Current $155.00K.
| Period end | Unbilled Receivables, Current |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 |
| 2025-12-31 | $155.00K 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |